Previous Close | 0.8700 |
Open | 0.8600 |
Bid | 0.8200 |
Ask | 0.9400 |
Strike | 30.00 |
Expire Date | 2024-01-19 |
Day's Range | 0.8600 - 0.8700 |
Contract Range | N/A |
Volume | |
Open Interest | 5.82k |
Yahoo Finance's Julie Hyman breaks down leading business headlines today regarding M&A activity and leadership changes.
NEW YORK & SAINT-HERBLAIN, France, August 08, 2022--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15.
BioNTech (NASDAQ: BNTX), the out-of-nowhere German biotech that shot to prominence with the coronavirus vaccine it developed with Pfizer (NYSE: PFE), wasn't having a great Monday. For its second quarter, BioNTech's revenue was just under 3.2 billion euros, or $3.3 billion, while its net profit stood at 1.67 billion euros. In that frame, BioNTech's top line was a bit over 5.3 billion euros, and it netted almost 2.79 billion euros in profit.